Conclusion 5-2

Compounded bioidentical hormone therapy (cBHT) pellet formulations may be difficult to compound given the complexity of drug delivery mechanism, lack of required bioavailability testing, insufficient guidance for compounders, and the need for specialized equipment. Given the broad scope of available cBHT pellet formations marketed for use, and questions regarding difficulty in compounding, there are concerns for safety and effectiveness.

From: 5, Compounded Bioidentical Hormone Preparations

Cover of The Clinical Utility of Compounded Bioidentical Hormone Therapy
The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Replacement Therapy; Jackson LM, Parker RM, Mattison DR, editors.
Washington (DC): National Academies Press (US); 2020 Jul 1.
Copyright 2020 by the National Academy of Sciences. All rights reserved.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.